Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited (Ranbaxy) is engaged in the manufacturing, marketing and distribution of pharmaceutical ingredients. The product portfolio of the company includes Simvastatin, CoAmoxyclav, inter alia, Amoxycillin, Ciprofloxacin, Isotretinon and Cephalexin. The major markets of the company`s products include India, the US, Europe, Russia, South Africa and Brazil. The company`s manufacturing facilities are located in various nations, namely, China, India, Brazil, Malaysia, Nigeria, Ireland, Japan, Romania, South Africa, Vietnam and the US. It serves customers in over 125 countries worldwide. Ranbaxy holds a research and development facility in Gurgaon, New Delhi, India. Ranbaxy is headquartered at Gurgaon in Haryana, India. In December 2009, the company has transferred its share in Ranbaxy (Guangzhou China) Limited (RGCL) to HNG Chembio Pharmacy Co. Ltd. (HNG). and it had sold 50% stake in its Japanese joint venture Nihon Pharmaceutical Industry Co., Ltd., to its partner Nippon Chemiphar Co., Ltd.The company reported revenues of (Rupee) INR 80,837.04 million during the fiscal year ended December 2009, an increase of 5.34% over 2008. The operating profit of the company was INR 10,097.62 million during the fiscal year 2009, whereas the company reported an operating loss of INR 15,000.31 million during 2008. The net profit of the company was INR 2,964.92 million during the fiscal year 2009, whereas the company reported a net loss of INR 9,512.05 million during 2008.